More Data Support Semaglutide for Obesity-Related HFpEF, Regardless of Diabetes Diagnosis

A pooled analysis from two harmonized, industry-funded trials shows improved obesity and symptoms and markers of HFpEF.

Heart failure with preserved ejection fraction (HFpEF) is highly prevalent in obesity. Metabolic interventions with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide have been recently tested in clinical trials. This pooled analysis combined individual-level data from two industry-funded trials with harmonized design in which 2.4 mg semaglutide or placebo was administered subcutaneously once weekly for 52 weeks in patients without diabetes (NEJM JW Cardiol Aug 25 2023 and N Engl J Med 2023; 389:1069) and with diabetes (NEJM JW Cardiol Apr 6 2024 and N Engl J Med 2024; 390:1394).

Based on data from 1145 randomized participants, semaglutide showed the following results compared with placebo:

Greater mean improvement in the Kansas…

Reviewing Author

Vlad G. Zaha, MD, PhD, FACC, FAHA

Disclosures

Grant/Research SupportCancer Prevention and Research Institute of Texas; National Institute of Health

Editorial BoardsCirculation

Leadership Positions in Professional SocietiesTexas Chapter of the American College of Cardiology (Section Chair, Cardio-Oncology)

Vlad G. Zaha, MD, PhD, FACC, FAHA

Disclosures

Grant/Research SupportCancer Prevention and Research Institute of Texas; National Institute of Health

Editorial BoardsCirculation

Leadership Positions in Professional SocietiesTexas Chapter of the American College of Cardiology (Section Chair, Cardio-Oncology)

More Data Support Semaglutide for Obesity-Related HFpEF, Regardless of Diabetes Diagnosis

Topics

Reviewing Author